Logo

Vicore and Nippon Shinyaku Collaborate for the Development and Commercialization of C21 in Japan

Share this
Vicore

Vicore and Nippon Shinyaku Collaborate for the Development and Commercialization of C21 in Japan

Shots:

  • Vicore Pharma and Nippon Shinyaku have signed an exclusive licensing agreement for the development and commercialization of the former's C21 for the treatment of idiopathic pulmonary fibrosis (IPF) in Japan
  • As per the agreement, Vicore retains all the global rights (excl. Japan) to C21 & will obtain $10M upfront, a total of $275M milestones for development and commercialization plus low 20s annual net sales-based tiered royalties while Nippon Shinyaku receives exclusive development & commercialization rights in Japan
  • Additionally, the company's P-IIa (AIR) trial revealed improvement in lung function with C21 in previously untreated IPF patients. A global P-IIb (ASPIRE) study is anticipated in H1’24

Ref: Vicore | Image: Vicore

Related Newswire:- Capricor Entered into an Exclusive Commercialization and Distribution Agreement with Nippon Shinyaku for CAP-1002 to Treat Duchenne Muscular Dystrophy in Japan

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions